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Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4%
only. Gemcitabine is a ﬁrst line agent for advanced pancreatic therapy; however, its eﬃcacy is limited by its poor intracellular
metabolism and chemoresistance. Studies have been conducted in an eﬀort to improve gemcitabine treatment results by adding
other chemotherapeutic agents, but none of them showed any signiﬁcant advantage over gemcitabine monotherapy. We found
that 85% of human pancreatic tumors analyzed by in situ hybridization analyses showed moderated to strong expression of the
H19gene. Wedesignedapreclinical studycombininggemcitabinetreatmentandaDNA-based therapyforpancreaticcancer using
a non viral vector BC-819 (also known as DTA-H19), expressing the diphtheria toxin A chain under the control of the H19 gene
regulatory sequences. The experiments conducted either in an orthotopic and heterotopic pancreatic carcinoma animal model
showed better antitumor activity following the sequential administration of the vector BC-819 and gemcitabine as compared to
the eﬀect of each of them alone. The results presented in the current study indicate that treatment with BC-819 in combination
with gemcitabine might be a viable new therapeutic option for patients with advanced pancreatic cancer.
1.Introduction
In spite of the signiﬁcant progress in treatment of diﬀerent
kinds of cancers, pancreatic cancer still has a very low rate of
5-year survival. The majority of patients with carcinoma of
pancreashavealreadyunresectabletumorandmetastaticdis-
easeatpresentation.Anumberofstudieshavebeenconduct-
ed in an eﬀort to improve actual treatments by combining
chemotherapeutic agents and radiotherapy, but none has yet
shown more than a 10 month survival result [1, 2]. Given
thosefacts,theneedfornovelandeﬀectivetherapiesisessen-
tial.
Our group previously reported the use of a new DNA-
based therapy for cancer treatment in which the plasmid
BC-819 (also known as DTA-H19) drives the expression of
diphtheria toxin A chain by the regulatory sequence of the
H19 gene only into cancer cells [3, 4]. This therapy demon-
strated good results in treatment of bladder, colon liver
metastases, pancreatic and ovarian cancers [4–8]. We have
shown that BC-819 injected directly into the pancreatic
tumor induced a cytotoxic eﬀect in cancer cells without
aﬀecting the surrounding normal cells. Treatment with BC-
819 presents the possibilities of limiting or reversing tumor
progression and even shrinking the tumor to a resectable size
[7]. The level of DTA transcript monitored by RT-PCR ana-
lyses showed the presence of DTA transcript verifying that
the intratumoral injection of the plasmid leads to transfec-
tion and expression of the DTA gene [7]. Intratumoral injec-
tions of BC-819 in a syngeneic hamster orthotopic tumor
model or in subcutaneous human pancreatic tumor devel-
oped in a nude mouse model showed signiﬁcant eﬃcacy
in decreasing tumor growth progression. However, it is
only local therapy which may not have systemic eﬀect.
Therefore, this local control therapy should be combined
with systemic chemotherapy that, probably, may improve
tumor response and survival. The present work evaluates2 ISRN Oncology
the possible advantages of local treatment of pancreatic can-
cer with BC-819 in combination with systemic administra-
tion of gemcitabine, the standard of care in pancreatic cancer
therapy. As these two drugs induce cell growth arrest by two
diﬀerent mode of action, it is hypothesized that an additive
eﬀect will be observed which will force the cells to enter into
apoptosis.
This work was designed to demonstrate that a combi-
nation of eﬀective local control of the tumor with systemic
therapy can improve the results of the treatment.
2.MaterialsandMethods
2.1. Cell Lines and Drug Solutions. The human ductal adeno-
carcinoma cell line CRL-1469 was obtained from the Ameri-
can Type Culture Collection (ATCC; Rockville, MD, USA)
and cultured in 90% DMEM-F12 medium and 10% fetal
bovine serum (FBS). The hamster pancreatic ductal carci-
noma cell line PC.1-0 was kindly provided by Dr. Buscail L.
(Institut National de la Sant´ e et de la Recherche M´ edicale
U531, Institut Louis Bugnard, Institut Federatif de Recher-
che-31, Centre Hospitalier Universitaire Rangueil, Toulouse,
France) and was cultured in 90% RPMI-1640 medium sup-
plemented with 10% FBS. Antibiotic solution penicillin
(180units/mL), streptomycin (100μg/mL), and amphoteri-
cin-B (0.2μg/mL) were added to all medium solution.
Gemcitabine (Eli Lilly) was diluted in saline.
2.2. Plasmids Preparation. The reporter plasmid Luc-H19
(which expresses the luciferase gene under the control of the
H19 promoter) and the BC-819 construct were prepared as
previously described [3, 4].
2.3. Orthotopic Model for Pancreatic Cancer. The hamster
model of pancreatic cancer was described in previous studies
[7,9],5-6-week-oldmaleSyriangoldenhamsters(70–80grs)
were purchased from Harlan and used to generate the ortho-
topic model. After anesthetization by subcutaneous injection
ofKetamine andXylazine(85mg/kg and15mg/kg, resp.)the
pancreas was surgically exposed and hamster pancreatic car-
cinoma cells (PC1-0) derived from a pancreatic ductal carci-
noma induced by N-nitrosobis (2-oxopropyl) amine were
injected into the pancreas of 6-7-week old Syrian Golden
Hamsters (n = 24). After 7 days, 100% of the animals pre-
sented a single tumor in their pancreas. The animals were
randomly divided into one of the following groups: untreat-
ed control, gemcitabine alone, and BC-819 + gemcitabine;
each group contained 8 animals. The control and the gem-
citabine groups received 25μL PBS by intratumoral injec-
tion, while the BC-819-treated group received 50μgo fB C -
819 in a ﬁnal volume of 25μL PBS. The intratumoral injec-
tion was performed at day 7 following the injection of
tumor cells. Gemcitabine (50mg/kg) treatment was begun
from day 11 and given twice weekly by intraperitoneal injec-
tion (IP). Tumor diameter measurements were taken before
intratumoral treatment and before sacriﬁce.
Animals were then sacriﬁced at day 18 at which time
the tumors were measured and the abdominal cavity was
searched for visible metastases. Tumors were excised, weigh-
ed, and their ex vivo dimensions were recorded.
The tumor volume was calculated as V = W2 × L/2,
where L = length and W = width, using width as the smaller
dimension. Tumor growth progression (TGP) was calculated
according to the following formula: TGP (%) = [(T ×
100/t)]−100, where t is the volume of tumor at beginning of
the treatment and T is volume of the same tumor at the end
of the treatment.
The tumors were ﬁxed in formalin, processed, and
embedded in paraﬃn for pathology studies. All the tumors
were histologically deﬁned as pancreatic cancer.
2.4. Toxicity Test. T h eb l o o do f4h a m s t e r sa te a c hg r o u p
was collected for the study of renal and liver function, blood
counting (including CBC + diﬀerential, creatinine, calcium,
phosphorus, urea, glucose, bilirubin, total protein, albumin,
globulin, cholesterol, alkaline phosphatase, SGPT, SGOT,
sodium, potassium, chloride).
2.5. Heterotopic Model for Pancreatic Cancer. In vivo local
tumor growth experiments were carried out in a subcuta-
neous xenograft model as described in a previous study [7].
Conﬂuent CRL-1469 human pancreatic carcinoma cells
were injected subcutaneously into the back of athymic
nude mice (5-6-week-old and 20–30 grams) purchased from
Harlan (Zeist, The Netherlands). Tumor-bearing mice were
randomized when tumors reached approximately 6mm dia-
meter. After tumor development (30 days), three BC-
819 administrations were performed, with a 2-day interval
between each treatment, by direct injection into the tumor
at days 0, 2, and 4. Treatment consisted of 25μg plasmid
(BC-819 for treated group and 5% w/v glucose for control
group) mixed with the transfectant polyethylenimine (Poly-
plus, Illkirsh, France) (N/P ratio = 6) diluted in 50μLo f
5% w/v glucose. Mice were randomly divided into one of
the following groups (N = 7 per group): control (glucose
5%), BC-819 alone, gemcitabine alone, and BC-819 + gem-
citabine. Animals received 2 injections of either gemcitabine
(150mg/kg) or saline by IP administration at days 37 and 41
following cells implantation.
To test survival, an additional xenograft model was used
using pancreatic carcinoma cells from hamster [10]. Con-
ﬂuent PC1-0 cells were trypsinized and resuspended in PBS
X 1. 1.5 × 105 cells in a ﬁnal volume of 100μLa n dw e r e
injected subcutaneously into the back of athymic nude mice
(5-6-week-old and 20–30 grams). After tumor development
(10 days), 3 treatments of plasmid vectors were given, with
a 2-day interval between each treatment, by direct injection
into the tumor. Treatment consisted of 25μg plasmid (BC-
819 for treated group and Luc-H19 reporter plasmid for
controlgroup)mixedwiththetransfectantpolyethylenimine
(Polyplus) (N/P = 6) diluted in 50μLo f5 %w / vg l u c o s e .
Mice were randomly divided into 4 groups (N = 4), includ-
ing Luc-H19 (control), BC-819, Luc-H19 + gemcitabine,
BC-819 + gemcitabine. Animals received either gemcitabine
(150mg/kg) or saline by IP administration at days 17 and
20 following cells implantation. Mice were sacriﬁced when
tumor reached a diameter larger than 13mm.ISRN Oncology 3
Table 1: Metastases observation developed in the hamster orthotopic pancreatic carcinoma model. Abdominal cavity was searched for
metastases in the animals groups described in Figures 1(a) and 1(b).
Treatment No metastases Few metastases (<4) Numerous metastases (>4)
BC-819 + gemcitabine 100%
Gemcitabine 37% 63%
No treatment 100%
No treatment Gemcitabine
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Figure 1: Sequential administration of BC-819 and gemcitabine in a hamster orthotopic pancreatic carcinoma model. (a) Average of ex
vivo tumor volume of the nontreated, gemcitabine, and BC-819 + gemcitabine treated groups measured after sacriﬁce (day 18). Asterisks
indicate signiﬁcant diﬀerence after BC-819 + gemcitabine compared with no treatment or gemcitabine alone (∗P<0.05, ∗∗P<0.01,
and ∗∗∗P<0.001). (b) Average of tumor growth progression of the nontreated, gemcitabine, and BC-819 + gemcitabine treated groups
calculated as the ratio of tumor size at the end of the experiment (day 18) compared to the size before treatment (day 7).
All experiments were performed according to the rules of
the Animal Ethics Committee.
3. Results
3.1. BC-819 Treatment in Two Diﬀerent Animal Models of
Pancreatic Cancer
3.1.1. Antitumor Eﬀect following Sequential Administration of
BC-819 and Gemcitabine in a Hamster Orthotopic Pancreatic
Carcinoma Model. As expected, gemcitabine treatment was
eﬀective in inhibiting the tumor growth as compared to the
control group. However, the sequential use of BC-819 and
gemcitabine demonstrated further advantages in reducing
the tumor burden (Figures 1(a) and 1(b)). The ex vivo tumor
volume determined at the end of the experiment showed
that compared to the control group (no treatment), the
gemcitabine group was reduced by 62% while the BC-819
plus gemcitabine group displayed tumors with a size reduced
by 83% (P<0.000005). The tumor volume in the sequential
use of BC-819 and gemcitabine group was also signiﬁcantly
lower when compared to the gemcitabine group alone (P<
0.04) (Figure 1(a)). Similar results were obtained measuring
the tumor progression growth (TPG %) (Figure 1(b)). The
control group showed 780% increment in tumor size, the
gemcitabine group showed approximately 200%, while the
BC-819 + gemcitabine group showed a 6% decrease in the
tumorgrowththatissigniﬁcantlylowerthanthegemcitabine
group alone (P<0.01).
Metastases occurrence was also analyzed: all animals in
the control group showed multiple visible metastases at the
end of the experiment, as compared to 63% of the animals
treated with gemcitabine showing less than 4 metastases, and
to 100% of the animals treated with BC-819 and gemcitabine
showing no visible metastases (Table 1).
There was no evidence of toxicity in any treatment group
based on animal appearance or weight loss. There were also
no signiﬁcant changes in hematology and chemistry in the
BC-819 + gemcitabine treated group as compared to the
untreated group.
In order to test the systemic toxicity of BC-819 given
in combination with gemcitabine, several organ samples
were collected from animals treated with BC-819 and gem-
citabine at terminal histopathology examination. No gross
or microscopic signiﬁcant alterations were noted in the4 ISRN Oncology
(a) (b)
Figure 2: Histopathology analyses in orthotopically induced tumors in the pancreas of hamsters treated either with Luc-H19 + gemcitabine
(a) or BC-819 + gemcitabine. (b) The arrows in pictures (a) and (b) mark the necrotic area (X10 original magniﬁcation for picture). An
extensive area of necrotic tissue it is clearly shown in the BC-819-gemcitabine-treated tumor only. Slides were prepared from paraﬃnb l o c k
sections and stained with hematoxylin eosin.
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Figure 3: Sequential administration of BC-819 and gemcitabine in a subcutaneous human pancreatic tumor in nude mouse model. and
Conﬂuent CRL-1469 human pancreatic carcinoma cells were injected subcutaneously into the back of athymic nude mice. After tumor
development (30 days), three BC-819 administrations were performed, with a 2-day interval between each treatment, by direct injection
into the tumor at days 0, 2, and 4. Mice were randomly divided into one of the following groups: control (glucose 5%), BC-819 alone,
gemcitabine alone and BC-819 + gemcitabine. Average tumor growth progression of control (N = 7), BC-819 (N = 7), gemcitabine
(N = 7), and BC-819 + gemcitabine (N = 7) groups comparing the tumor volume measured at the end of the experiment to the volume
measured at the beginning.
following organs: pancreas, liver, lung, bowel, spleen, heart,
kidney, adrenal gland, lymph node, and gall bladder.
Histopathologic analysis showed that the sequential
treatment with BC-819 and gemcitabine increased the nec-
rotic area in the tumor in comparison with control groups
(Figure 2).
This study demonstrated that BC-819 used in sequential
use with gemcitabine is more eﬃcient than gemcitabine
alone at controlling the tumor growth progression (reﬂected
by lower tumors volume) and at preventing the occurrence
of metastases.
3.1.2. Antitumor Eﬀect following Sequential Administration
of BC-819 and Gemcitabine in a Subcutaneous Human Pan-
creatic Tumor in Nude Mouse Model. Local human pan-
creatic tumor growth experiments were carried out in a
subcutaneous xenograft model. This animal model has pro-
ven useful in the measurement of tumor progression and has
been reliable and reproducible.
Sequential use of BC-819 and gemcitabine resulted in a
signiﬁcant delay in tumor growth progression as compared
to the other groups (Figure 3). The heterotopic model
using CRL-1469 cells showed that 3 intratumoral injections
of BC-819 alone at 2-day interval or 2 intraperitoneal
administrations at 4-day interval of gemcitabine alone were
able to decrease tumor growth as compared to the untreated
control group; however, the combination of BC-819 and
gemcitabine was signiﬁcantly more eﬀective.
A signiﬁcant diﬀerence in tumor growth progression was
found between the group of BC-819 + gemcitabine versus
gemcitabine alone (P<0.044) and BC-819 alone (P<0.05)
(Figure 3).ISRN Oncology 5
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Figure 4: The eﬀect of sequential administration of BC-819 and gemcitabine on tumor progression and on the survival of a nude mice
heterotopic pancreatic carcinoma model. Pancreatic carcinoma cells from hamster (PC1-0 cells) were injected subcutaneously into the back
of athymic nude mice. After tumor development, 3 treatments of plasmid vectors were given, with a 2-day interval between each treatment,
by direct injection into the tumor. Mice were randomly divided into 4 groups of 4 animals each and received the following treatments: Luc-
H19 (control vector), BC-819, Luc-H19 + gemcitabine, BC-819 + gemcitabine. Mice were sacriﬁced when tumor reached a diameter larger
than 13mm. (a) Average tumor growth progression comparing the tumor volume measured after the last treatment to the volume measured
before the ﬁrst treatment. (b) Percentage of mice with a tumor diameter <13mm as a function of time after the start of the treatment. The
days or treatment are marked by arrows.
Both groups treated with gemcitabine alone or sequen-
tially with BC-819 showed similar weight loss (up to 20%)
as compared to the control group or the group treated with
BC-819 alone (data not shown).
3.1.3. Evaluation of Survival after Sequential Administration
of BC-819 and Gemcitabine in a Subcutaneous Hamster
PancreaticTumorinNudeMouseModel. Localtumorgrowth
and survival experiments were carried out in a subcutaneous
xenograft model.
Sequential use of BC-819 and gemcitabine resulted in a
signiﬁcant diﬀerence in tumor growth progression as com-
pared to the other treatment groups (Figure 4(a)). The
heterotopic model using PC-1.0 hamster pancreatic carcin-
oma cells also showed delay in tumor growth after adminis-
tration of either BC-819 alone or Luc-H19 (control vector) +
gemcitabine and further delay when the combination of BC-
819 and gemcitabine was used. The inhibiting eﬀect follow-
ing the combined treatment of BC-819 and gemcitabine in
t h et u m o rg r o w t ha sc o m p a r e dt oe a c ho ft h ed r u g sa l o n e
wasalsomoresigniﬁcantinthehumanpancreaticcarcinoma
xenograft.
21 days after the ﬁrst treatment the survival rate in the
groupofmicetreatedwithbothBC-819andgemcitabinewas
100% while in the group treated with BC-819 alone was 50%
and 0% in the groups treated with either the combination of
gemcitabine and Luc-H19 or Luc-H19 alone (Figure 4(b)).
A signiﬁcant diﬀerence in tumor growth progression was
found between the group of BC-819 + gemcitabine versus
Luc-H19 + gemcitabine (P<0.037) (Figure 4(a)).
The results show a signiﬁcant increase in survival of the
group treated with BC-819 + gemcitabine versus Luc-H19 +
gemcitabine or BC-819 alone (Figure 4(b)).
Along with moderate diﬀerences in the tumor progres-
sion between the mice treated with BC-819 alone and those
treated with the combination of BC-819 and gemcitabine,
survival in the last group was also signiﬁcantly longer.
4. Discussion
The present study proposes a successful approach for the
treatment of pancreatic cancer combining conventional
chemotherapy used nowadays and a DNA-based therapy
expressing a toxin under the control of regulatory sequences
of a diﬀerentially expressed gene, the H19 gene. The human
H19 gene is an imprinted gene, expressed from the maternal
allele in several tissues during embryo development and
repressed right after birth [11]. H19 gene was shown to
be reexpressed in several cancer tissues derived from those
tissues which expressed the gene during embryonic develop-
ment [12] such as bladder cancer [13], hepatocellular carcin-
oma [14], adrenocortical tumors [15], choriocarcinoma
[16], colorectal cancer [17], ovarian carcinoma and lung car-
cinoma [18]. H19 RNA shares all known characteristics of
messenger RNA but has no known protein product [19].
H19 RNA contributes signiﬁcantly to several aspects of the
malignant phenotype including proliferation, hypoxic stress
response, angiogenesis, metastasis, and multidrug resistance
[20, 21]. Cancer cells devoid of H19 expression encounter a
very signiﬁcant retardation of tumor growth in vivo [22]. It6 ISRN Oncology
was previously demonstrated that the BC-819 construct was
able to kill tumor cells both in vitro and in vivo in animal
models for bladder cancer, ovarian cancer, colorectal liver
metastases [3–6, 8]. An expression of H19 gene in 85% of the
analyzed human pancreatic cancer samples determined by in
situ hybridization analysis allowed us to suggest eﬀectiveness
of the BC-819 construct in this disease. Indeed, direct
intratumoral injections of BC-819 caused tumor growth
retardation in pancreatic cancer animal models [7].
However, this treatment delaying tumor growth may not
eﬃciently prevent metastatic spread. The combination of
local therapy with systemic chemotherapeutic agent is very
likely to be more eﬀective in the control of the disease [23–
26]. Thus, intraperitoneal administration of gemcitabine
may inhibit metastatic spread simultaneously reducing pri-
mary tumor growth. Both BC-819 and gemcitabine dis-
play a pharmacological eﬀect on cellular growth inhibition
gemcitabine acts upstream in the cell cycle by inhibiting
DNA synthesis in all cells engaged in mitosis [23–26] while
BC-819 acts downstream by inhibiting protein synthesis in
tumorcellsexhibitinghighH19geneexpressionlevels[3].As
these two products induce cell growth arrest by two diﬀerent
mode of action, it is hypothesized that an additive eﬀect
will be observed which will force the cells to enter into
apoptosis. Indeed, in both heterotopic and orthotopic pan-
creatic cancer animal models, intraperitoneal gemcitabine
treatment aﬀected tumor growth and reduced the number
of developed metastases as compared to the control group.
Nevertheless, as we suggested, the sequential use of BC-819
and gemcitabine was found signiﬁcantly more eﬀective. It
provided not only delay in tumor progression, but regression
of tumor size in contrast to other groups (Figures 1(a)
and 1(b)). The ex vivo tumor volume in the sequential use
of BC-819 and gemcitabine group was signiﬁcantly low-
erwhencomparedtothegemcitabinegroupalone(P<0.04)
(Figure 1(a)). Our previous studies [7] showed that BC-
819 treatment was eﬀective in inhibiting the tumor growth
compared with the Luc-H19 treated tumors; thus, excluding
an o n s p e c i ﬁ ce ﬀect of the BC-819 plasmid and supporting
an speciﬁc antitumor eﬀect. The orthotopic experiment also
showed that the combination of BC-819 and gemcitabine
treatment aﬀects metastasis occurrence stronger than gem-
citabine alone. In contrast to the control group where all
the animals showed multiple visible metastases at the end
of the experiment, 63% of the animals treated with gem-
citabine alone showed a few number of metastases, whereas
100% of the animals treated with BC-819 and gemcitabine
did not show visible metastases at all (Table 1). Tumor
invasion and metastasis are the major causes of treatment
failure and death in pancreatic cancer. Therefore, the preven-
tion of metastatic spread in animals treated with the sequen-
tial administration of BC-819 and gemcitabine indicates
that the combined treatment may overcome the limitations
associated with single molecule treatment that may also
explain the beneﬁt in survival rate in the heterotopic mod-
el treated with sequential administration of BC-819 and
gemcitabine.
To date, some gemcitabine-containing combinations
have demonstrated modest improvement when compared to
gemcitabine alone, particularly in patients with good per-
formance status [27, 28]. Delay of tumor progression,
decrease in the metastatic process, and increase in the sur-
vival rate were achieved combining the systemic eﬀect of
gemcitabine with local destruction of tumor by BC-819.
These ﬁndings demonstrate potential advantages of com-
bination therapy strategies targeting multiple pathways in
pancreatic cancer treatment. The rationale to use BC-819
in combination with gemcitabine in patients with locally
advanced adenocarcinoma of the pancreas is thus to maxi-
mize tumor cell death. BC-819 given locally in combination
with systemic chemotherapy may provide additional thera-
peutic beneﬁt for the treatment of pancreatic cancer.
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